Reportlinker.com

Reportlinker.com

March 27, 2008 08:12 ET

Learn About the World Osteoporosis Therapeutics Market

LONDON, UNITED KINGDOM--(Marketwire - March 27, 2008) - Reportlinker.com announces that a new market research report related to the Pharmaceutical industry is available in its catalogue.

World Osteoporosis Therapeutics Market

This report analyzes the worldwide markets for Osteoporosis Therapeutics in Millions of US$. The specific product segments analyzed are Bisphosphonates, ERT Drugs, SERMs, and Calcitonins. The report provides separate comprehensive analytics for the US, Japan, Europe, and Rest of World. Annual forecasts are provided for each region and product segment for the period of 2000 through 2015. The report profiles 52 companies including many key and niche players worldwide such as Eli Lilly and Company, F.Hoffmann-La Roche Ltd, Merck & Co., Inc., Novartis AG, Novo Nordisk, Organon, Procter & Gamble Pharmaceuticals, Inc., Sanofi-Aventis SA, Servier SA, Solvay Pharmaceuticals, Inc., Unigene Laboratories, Inc., and Wyeth. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

CONTENTS

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations I-1

Disclaimers I-2

Data Interpretation and Reporting Level I-2

Quantitative Techniques & Analytics I-3

Product Definitions and Scope of Study I-3

Bisphosphonates I-3

Hormone Replacement Therapy/Estrogen Replacement Therapy I-3

Estrogens I-4

Estrogens/Progesterones I-4

Calcitonins I-4

Selective Estrogen Receptor Modulators (SERMs) I-4

Other Therapeutics I-4

II. EXECUTIVE SUMMARY

1. Outlook II-1

Regional Market Perspective II-1

United States II-1

Europe II-1

Japan II-2

2. Industry Overview II-3

Osteoporosis Therapeutics: An Evolutionary Scan II-3

"A Sketch of the Present Industry Scenario" II-3

Facts & Figures: The Osteoporosis Primacy II-3

Snapshots II-3

Table 1: Prevalence of Osteoporosis and Osteopenia in Major Markets including US, Germany, Italy, France, UK, Spain and Japan: 2003-2013 (In Millions) (includes corresponding Graph/Chart) II-4

Factors Influencing Demand II-4

Competitive Landscape II-4

Table 2: Worldwide Osteoporosis Market (2006): Percentage Breakdown by Leading Players-Merck, Novartis, Eli Lilly, Procter & Gamble, Wyeth, and Others (includes corresponding Graph/Chart) II-5

Table 3: Worldwide Osteoporosis Market (2005): Dollar Sales of Leading Osteoporosis Drugs-Fosamax, Actonel, Evista, Miacalcic, and Forteo (In US$ Thousands) (includes corresponding Graph/Chart) II-5

Table 4: Leading Osteoporosis Therapies and its Cost per Day II-5

Market Trends and Issues II-6

Can New Treatments Beat the Gold Standard? II-6

Oral Calcitonin Likely to Emerge as Wonder Drug II-6

New Bisphosphonates Challenge Established Brands II-7

Side Effects of HRT Fuel Natural Alternatives Sales II-7

Bone Formation Drugs Augur New Prospects II-7

A Sneak Into Various Options in Antiresorptives, Anabolic Therapeutics II-8

Estrogen Replacement Therapy: Will Dosing Make a Difference? II-9

Is Prevention Always Better Than Cure? II-9

Peptide-Based Osteoporosis Therapy Gaining Ground II-9

Polymorphism- A Potent Diagnostic Marker II-9

Bisphosphonates - The Other Side II-9

Efficacy of Evista Under the Scanner II-10

3. Major Therapeutic Classes: A Global Perspective II-11

ERT Drugs II-11

Ups and Downs in the ERT Market II-11

Outlook II-11

Bisphosphonates II-11

The leading Therapeutic Market. II-11

SERMS II-12

Market Overview II-12

Calcitonins II-12

Market Overview II-12

4. Product Overview II-13

The "Silent Thief" II-13

An Introduction to Bone Physiology II-13

How Osteoporosis Steps In II-13

Osteoporosis: Major Types II-14

Primary Osteoporosis II-14

Secondary Osteoporosis II-14

Osteoporosis - The Aftermath II-15

Prevention: The Only Better Way Out II-15

Osteoporosis Therapies: A Cursory Glance II-15

Nondrug Therapy II-15

Drug Therapy II-16

Major Osteoporosis Therapeutic Classes: A Brief Review II-16

Bisphosphonates II-16

Classification of Bisphosphonates II-16

Etidronate II-16

Alendronate II-17

Risedronate II-17

Calcitonin: A Relatively Safer Therapeutic II-17

What It Is II-17

What It Does II-17

Major Types II-17

Salmon Calcitonin II-17

SERM: A Breakthrough II-18

Raloxifene: The First SERM II-18

SERMs: The Positive Angle II-18

SERMs: The Negative Side II-18

Hormone Replacement Therapy/Estrogen Replacement Therapy: The Longstanding Therapeutic II-18

ERT: The Positive Side II-19

The Negative Angle to ERT II-19

Tereparatide: The First Anabolic Agent II-19

Composition II-19

Forteo: A Leading Brand II-19

Major Therapeutic Classes at a Glance II-20

Osteoporosis Therapeutics: A Peek into the Major Brands II-21

New Drugs/Drug Classes in Pipeline II-22

SERMs II-22

Bisphosphonates II-22

Zoledronic Acid: II-22

Pamidronate: II-22

Reclast II-22

Calcitonin II-22

Parathyroid Hormone (PTH) II-22

Denosumab (AMG-162) II-23

Combination Therapy II-23

5. Major Clinical Trials/Findings II-24

End-Stage Therapies (Under Development) for Osteoporosis Prevention/Cure II-24

GSK & NPS Collaborate for Phase II Clinical Study of Calcilytics II-24

Radius Initiates Phase II Trials for BA058 II-25

Novartis and Nordic Initiate Phase III Clinical Trial of Oral Salmon Calcitonin II-25

Medivir Initiates First Human Trials for MIV-701 II-25

Osteologix Begins Phase II Trial of NB S101 II-26

Zelos and Nektar Initiates Phase I Clinical Trial of Ostabolin-C(TM) II-26

Acceleron Initiates Phase I Clinical Trial of ACE-011 II-27

Positive Results from Reclast Clinical Trials II-27

6. Product Introductions/Approvals II-28

P&G Receives FDA Approval for New Dosage of Actonel II-28

Takeda Introduces Benet(R) for Osteoporosis Treatment II-28

Labtec Obtains Approval to Market Hormone Replacement Patch in Europe II-28

Wyeth Obtains Conditional Approval for Osteoporosis Drug from FDA II-28

Merck's New Dosage of FOSAMAX PLUS D Gains FDA Approval II-28

Japanese Pharma Majors Receive Approval for Generic Osteoporosis Drug II-29

Roche and GlaxoSmithKline Introduce Bonviva II-29

GlaxoSmithKline and Roche Co-Promoted Boniva Receives FDA Approval II-30

Nycomed's Preotact Recommended for Approval in Europe II-30

Procter & Gamble and Sanofi-Aventis' Actonel Approved for Male Osteoporosis II-30

Upsher-Smith Laboratories Rolls Out Fortical Nasal Spray II-30

Teva Receives Tentative FDA Approval for Risedronate Sodium Tablets II-31

GlaxoSmithKline and Roche Receive Approval for Bonviva in Switzerland II-31

Roche's Once-a-month Bisphosphonate Gets FDA Nod II-31

Actonel with Calcium(R) Obtains FDA Approval II-31

FDA Approves Unigene's Nasal Calcitonin II-32

Novavax's ESTRASORB(R) Clears FDA Hurdle II-32

Menostar(TM) Secures FDA Approval II-32

Bonviva Gains European Commission Approval II-32

Schering Introduces New Hormone Therapy Products II-32

Eli Lilly Launches Evista in Japan and China II-32

Proteolos Bags EU Approval II-33

Forcaltonin(R) Secures European Approval II-33

Ministry of Health Labor and Welfare Approves P&G's Actonel(R) II-33

Eli Lilly's Osteoporosis Drug Obtains US Approval II-33

Vivelle Dot 0.025 ERT Patch from Novogyne II-33

Novartis Rolls Out Estradot II-33

Pfizer Launches FemHRT II-34

Ligand Unveils LGD2226 II-34

7. Recent Industry Activity II-35

Schering-Plough Acquires Organon BioSciences II-35

Faes Farma Signs Marketing Agreement with Roche and GlaxoSmithKline II-35

Alethia and Emerillon Collaborate on Osteoporosis Therapies II-35

Ipsen Enters into Co-marketing Agreement with MSD II-35

Unigene Enters into Agreement with Novartis II-36

Pharming Group Granted Subsidies to Develop Osteoporosis Drugs II-36

Procter & Gamble Terminates Nasal Spray Collaboration with Nastech Pharmaceutical II-36

Pharming Group Acquires DNage II-36

Amgen Acquires Abgenix II-37

P&G Licenses Osteoporosis Nasal Spray Rights from Nastech II-37

Eli Lilly to Close Basingstoke Plant II-37

Galapagos Acquires Drug Discovery Platform of Discovery Partners II-38

Duravest Acquires Bio-Magnetic Therapy II-38

Galapagos Acquires ProStrakan's ProSkelia II-38

Roche Inks a Marketing Agreement with Elder Pharma II-38

Chugai and Taisho Sign a Joint Development and Marketing Agreement II-39

Theragenex Signs a Licensing Agreement with Zylera II-39

Radius Acquires Licensing Agreement for Eisai's SERMs II-39

Alkermes Partners with Eli Lilly to Develop and Market PTH Formulation II-39

Radius Acquires Exclusive Rights to Karo Bio's SARMS II-40

Unigene Enters into Agreement with Tzamal Bio II-40

Galapagos Acquires Inpharmatica II-40

Bio-Rad Acquires Provalis Medical Diagnostics Operations II-40

Daiichi Sankyo to Market Evista in Europe II-41

Biocon Acquires Nobex II-41

Radius and Ipsen Enters into Licensing Agreement II-41

Novartis Acquires Hexal AG II-42

Nippon Chemiphar Signs Agreement with Velcura Therapeutics II-42

Biopotential Capital Acquires Osta Biopharma II-42

Dnage Commences DNA Research Programme for Osteoporosis Therapeutics II-42

Nastech Initiates Phase I Study of PTH 1-34 II-42

SEQUENOM Collaborates with P&G Pharmaceuticals II-43

Novartis Extends Alliance with Emisphere II-43

Eli Lilly Markets Forteo in Europe II-43

Avesthagen Co-develops Osteoporosis Drug with CCBR II-43

Nastech Signs Agreement with Par Pharmaceutical, Inc II-43

Unigene and Novartis in a Licensing and Manufacturing Agreement II-43

8. Developments in the Recent Past II-44

Wyeth Ties Up with Tanox and Galapagos II-44

Galapagos and P&G Collaborate to Develop Osteoporosis Drugs II-44

Unigene Grants License to Faran II-44

Genome Collaborates with Amgen II-44

Unigene Joins Hands with Shijiazhuang II-44

Unigene, GSK Signs License Collaboration II-44

Unigene and Upsher-Smith in a Licensing Agreement II-45

Celgene and Novartis Embark on Joint Research for SERMs II-45

Roche, GSK Signs Global Agreement II-45

Novogyne Procures CombiPatch(TM) from Aventis II-45

9. Focus on Select Global Players II-46

Eli Lilly and Company (US) II-46

F.Hoffmann-La Roche Ltd (Switzerland) II-46

Merck & Co., Inc. (US) II-46

Novartis AG (Switzerland) II-46

Novo Nordisk A/S (Denmark) II-46

Organon II-47

Procter & Gamble Pharmaceuticals Inc. (US) II-47

Sanofi-Aventis SA (France) II-47

Servier SA (France) II-48

Solvay Pharmaceuticals Inc. (US) II-48

Unigene Laboratories, Inc. (US) II-48

Wyeth (US) II-48

10. Global Market Perspective II-50

Table 5: World Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Geographic Region - US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart) II-50

Table 6: World Long-Term Projections for Osteoporosis Therapeutics by Geographic Region - US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart) II-51

Table 7: World 10-Year Perspective for Osteoporosis Therapeutics by Geographic Region - Percentage Breakdown of Dollar Sales for US, Japan, Europe, and Rest of World Markets for Years 2000, 2007 & 2010 (includes corresponding Graph/Chart) II-51

Table 8: World Recent Past, Current & Future Analysis for Bisphosphonates by Geographic Region - US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart) II-52

Table 9: World Long-Term Projections for Bisphosphonates by Geographic Region - US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart) II-52

Table 10: World 10-Year Perspective for Bisphosphonates by Geographic Region - Percentage Breakdown of Dollar Sales for US, Japan, Europe, and Rest of World Markets for Years 2000, 2007 & 2010 (includes corresponding Graph/Chart) II-53

Table 11: World Recent Past, Current & Future Analysis for ERT Drugs by Geographic Region - US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart) II-54

Table 12: World Long-Term Projections for ERT Drugs by Geographic Region - US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart) II-54

Table 13: World 10-Year Perspective for ERT Drugs by Geographic Region - Percentage Breakdown of Dollar Sales for US, Japan, Europe, and Rest of World Markets for Years 2000, 2007 & 2010 (includes corresponding Graph/Chart) II-55

Table 14: World Recent Past, Current & Future Analysis for SERMs by Geographic Region - US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart) II-56

Table 15: World Long-Term Projections for SERMs by Geographic Region - US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart) II-56

Table 16: World 10-Year Perspective for SERMs by Geographic Region - Percentage Breakdown of Dollar Sales for US, Japan, Europe, and Rest of World Markets for Years 2000, 2007 & 2010 (includes corresponding Graph/Chart) II-57

Table 17: World Recent Past, Current & Future Analysis for Calcitonins by Geographic Region - US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart) II-58

Table 18: World Long-Term Projections for Calcitonins by Geographic Region - US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart) II-58

Table 19: World 10-Year Perspective for Calcitonins by Geographic Region - Percentage Breakdown of Dollar Sales for US, Japan, Europe, and Rest of World Markets for Years 2000, 2007 & 2010 (includes corresponding Graph/Chart) II-59

III. MARKET

1. United States III-1

A.Market Analysis III-1

Industry Overview III-1

Outlook III-1

Osteoporosis in the US: An Insight III-1

Osteoporosis - An Underserved Market? III-1

Statistical Review III-2

Table 20: Incidence of Osteoporosis in the US (2004) (includes corresponding Graph/Chart) III-2

Table 21: Osteoporosis Prevalence in Post-Menopause Women (includes corresponding Graph/Chart) III-3

Table 22: Number of Osteoporosis Patients Undergoing Osteoporosis Therapies (In Thousands) (includes corresponding Graph/Chart) III-4

Osteoporosis Prescription Market III-4

Table 23: US Osteoporosis Prescription Market (2004-2006): Percentage Share of Leading Drugs- Fosamax, Actonel, Evista, Boniva, Forteo and Others (includes corresponding Graph/Chart) III-4

Competitive Scenario III-4

Table 24: Leading Players in the US Osteoporosis Market (2004) - Market Share by Value Sales for Merck, Eli Lilly, Procter & Gamble/ Sanofi-Aventis and Others (includes corresponding Graph/Chart) III-5

Competitive Review by Segment III-5

Bisphosphonates III-5

Table 25: Leading Players in the US Bisphosphonates Market (2004) - Market Share by Value Sales for Merck and Procter & Gamble/ Sanofi-Aventis III-5

Table 26: Leading Players in the US Bisphosphonates Market (2008) - Market Share by Value Sales for Merck, Procter & Gamble/ Sanofi-Aventis, Novartis and Roche/GSK (includes corresponding Graph/Chart) III-6

SERMs III-6

Calcitonins III-6

Patent Expiry Catalog of Major Osteoporosis Drugs III-6

Product Launches/Approvals III-7

Strategic Corporate Developments III-10

Select US Players III-15

B.Market Analytics III-18

Table 27: US Recent Past, Current & Future Market Analysis for Osteoporosis Therapeutics by Product Group - Bisphosphonates, ERT Drugs, SERMs, Calcitonins and Others Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart) III-18

Table 28: US Long-Term Projections for Osteoporosis Therapeutics by Product Group - Bisphosphonates, ERT Drugs, SERMs, Calcitonins and Others Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart) III-19

Table 29: US 10-Year Perspective for Osteoporosis Therapeutics by Product Group - Percentage Breakdown of Dollar Sales for Bisphosphonates, ERT Drugs, SERMs, Calcitonins and Others for Years 2000, 2007 & 2010 (includes corresponding Graph/Chart) III-19

2. Japan III-20

A.Market Analysis III-20

Product Launches/Approvals III-20

Strategic Corporate Development III-21

B.Market Analytics III-22

Table 30: Japanese Recent Past, Current & Future Market Analysis for Osteoporosis Therapeutics by Product Groups - Bisphosphonates, ERT Drugs, SERMs, and Calcitonins Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart) III-22

Table 31: Japanese Long-Term Projections for Osteoporosis Therapeutics by Product Group - Bisphosphonates, ERT Drugs, SERMs, and Calcitonins Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart) III-22

Table 32: Japanese 10-Year Perspective for Osteoporosis Therapeutics by Product Group - Percentage Breakdown of Dollar Sales for Bisphosphonates, ERT Drugs, SERMs, and Calcitonins for Years 2000, 2007 & 2010 (includes corresponding Graph/Chart) III-23

3. Europe III-24

A.Market Analysis III-24

Outlook III-24

Forsteo: The First Anabolic Agent in Europe III-24

European Regulatory Restricts HRT III-24

Calcitonins Embraces New Label III-25

Table 33: European Market for Osteoporosis Therapeutics (2005): Market Share of Leading Players - Novartis, Merck, Wyeth, Novo Nordisk, Organon, Procter & Gamble, Schering, Solvay and Others (includes corresponding Graph/Chart) III-25

Product Launches/Approvals III-25

Strategic Corporate Developments III-27

Select European Players III-29

B.Market Analytics III-30

Table 34: European Recent Past, Current & Future Market Analysis for Osteoporosis Therapeutics by Geographic Region - France, Germany, The UK, Italy, Spain, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart) III-30

Table 35: European Long-Term Projections for Osteoporosis Therapeutics by Geographic Region - France, Germany, The UK, Italy, Spain, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart) III-31

Table 36: European 10-Year Perspective for Osteoporosis Therapeutics by Geographic Regions - Percentage Breakdown of Dollar Sales for France, Germany, The UK, Italy, Spain, and Rest of Europe Markets for Years 2000, 2007 & 2010 (includes corresponding Graph/Chart) III-31

Table 37: European Recent Past, Current & Future Market Analysis for Osteoporosis Therapeutics by Product Groups - Bisphosphonates, ERT Drugs, SERMs, and Calcitonins Independently Analyzed with Annual Sales Figures in US$

Million for Years 2000 through 2010 (includes corresponding Graph/Chart) III-32

Table 38: European Long-Term Projections for Osteoporosis Therapeutics by Product Group - Bisphosphonates, ERT Drugs, SERMs, and Calcitonins Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart) III-32

Table 39: European 10-Year Perspective for Osteoporosis Therapeutics by Product Group - Percentage Breakdown of Dollar Sales for Bisphosphonates, ERT Drugs, SERMs, and Calcitonins for Years 2000, 2007 & 2010 (includes corresponding Graph/Chart) III-33

3a. France III-34

A.Market Analysis III-34

Strategic Corporate Developments III-34

B.Market Analytics III-35

Table 40: French Recent Past, Current & Future Market Analysis for Osteoporosis Therapeutics by Product Groups - Bisphosphonates, ERT Drugs, SERMs, and Calcitonins Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart) III-35

Table 41: French Long-Term Projections for Osteoporosis

Therapeutics by Product Group - Bisphosphonates, ERT Drugs, SERMs, and Calcitonins Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart) III-35

Table 42: French 10-Year Perspective for Osteoporosis

Therapeutics by Product Group - Percentage Breakdown of Dollar Sales for Bisphosphonates, ERT Drugs, SERMs, and Calcitonins for Years 2000, 2007 & 2010 (includes corresponding Graph/Chart) III-36

3b. Germany III-37

Market Analysis III-37

Table 43: German Recent Past, Current & Future Market Analysis for Osteoporosis Therapeutics by Product Groups - Bisphosphonates, ERT Drugs, SERMs, and Calcitonins Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart) III-37

Table 44: German Long-Term Projections for Osteoporosis Therapeutics by Product Group - Bisphosphonates, ERT Drugs, SERMs, and Calcitonins Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart) III-38

Table 45: German 10-Year Perspective for Osteoporosis Therapeutics by Product Group - Percentage Breakdown of Dollar Sales for Bisphosphonates, ERT Drugs, SERMs, and Calcitonins for Years 2000, 2007 & 2010 (includes corresponding Graph/Chart) III-38

3c. The United Kingdom III-39

A.Market Analysis III-39

Osteoporosis Population Forecast in the UK III-39

Osteoporosis Population in the UK: 2004 -2009E III-39

Product Launches III-40

Strategic Corporate Developments III-40

B.Market Analytics III-41

Table 46: UK Recent Past, Current & Future Market Analysis for Osteoporosis Therapeutics by Product Groups - Bisphosphonates, ERT Drugs, SERMs, and Calcitonins Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart) III-41

Table 47: UK Long-Term Projections for Osteoporosis Therapeutics by Product Group - Bisphosphonates, ERT Drugs, SERMs, and Calcitonins Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart) III-42

Table 48: UK 10-Year Perspective for Osteoporosis Therapeutics by Product Group - Percentage Breakdown of Dollar Sales for Bisphosphonates, ERT Drugs, SERMs, and Calcitonins for Years 2000, 2007 & 2010 (includes corresponding Graph/Chart) III-42

3d. Italy III-43

Market Analysis III-43

Table 49: Italian Recent Past, Current & Future Market Analysis for Osteoporosis Therapeutics by Product Groups - Bisphosphonates, ERT Drugs, SERMs, and Calcitonins Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart) III-43

Table 50: Italian Long-Term Projections for Osteoporosis Therapeutics by Product Group - Bisphosphonates, ERT Drugs, SERMs, and Calcitonins Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart) III-44

Table 51: Italian 10-Year Perspective for Osteoporosis Therapeutics by Product Group - Percentage Breakdown of Dollar Sales for Bisphosphonates, ERT Drugs, SERMs, and Calcitonins for Years 2000, 2007 & 2010 (includes corresponding Graph/Chart) III-44

3e. Spain III-45

A.Market Analysis III-45

Strategic Corporate Development III-45

B.Market Analytics III-46

Table 52: Spanish Recent Past, Current & Future Market

Analysis for Osteoporosis Therapeutics by Product Groups - Bisphosphonates, ERT Drugs, SERMs, and Calcitonins Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart) III-46

Table 53: Spanish Long-Term Projections for Osteoporosis Therapeutics by Product Group - Bisphosphonates, ERT Drugs, SERMs, and Calcitonins Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart) III-46

Table 54: Spanish 10-Year Perspective for Osteoporosis Therapeutics by Product Group - Percentage Breakdown of Dollar Sales for Bisphosphonates, ERT Drugs, SERMs, and Calcitonins for Years 2000, 2007 & 2010 (includes corresponding Graph/Chart) III-47

3f. Rest of Europe III-48

A.Market Analysis III-48

Outlook III-48

Romania III-48

Strategic Corporate Developments III-48

Select Players in Rest of Europe III-49

B.Market Analytics III-51

Table 55: Rest of Europe Market for Osteoporosis

Therapeutics - Recent Past, Current & Future Analysis by Product Groups - Bisphosphonates, ERT Drugs, SERMs, and Calcitonins Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart) III-51

Table 56: Rest of Europe Long-Term Projections for Osteoporosis Therapeutics by Product Groups - Bisphosphonates, ERT Drugs, SERMs, and Calcitonins Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart) III-51

Table 57: Rest of Europe 10-Year Perspective for Osteoporosis Therapeutics by Product Group - Percentage Breakdown of Dollar Sales for Bisphosphonates, ERT Drugs, SERMs, and Calcitonins for Years 2000, 2007 & 2010 (includes corresponding Graph/Chart) III-52

4. Rest of World III-53

A.Market Analysis III-53

Outlook III-53

Prevalence of Osteoporosis in Various Region-At a Glance III-53

Korea III-53

Table 58: Leading Brands in the Korean Osteoporosis Therapeutics Market (2005): Percentage Share Breakdown by Dollar Sales for Fosamax, Atonel, Alend, Maxmarvil, and Others (includes corresponding Graph/Chart) III-53

China III-54

Schering Pharmaceutical Limited (China) - A Major Player III-54

Product Launch III-54

Strategic Corporate Developments III-54

B.Market Analytics III-56

Table 59: Rest of World Market for Osteoporosis Therapeutics - Recent Past, Current & Future Analysis by Product Groups - Bisphosphonates, ERT Drugs, SERMs, and Calcitonins Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart) III-56

Table 60: Rest of World Long-Term Projections for Osteoporosis Therapeutics by Product Groups - Bisphosphonates, ERT Drugs, SERMs, and Calcitonins Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart) III-56

Table 61: Rest of World 10-Year Perspective for Osteoporosis Therapeutics by Product Group - Percentage Breakdown of Dollar Sales for Bisphosphonates, ERT Drugs, SERMs, and Calcitonins for Years 2000, 2007 & 2010 (includes corresponding Graph/Chart) III-57

IV. COMPETITIVE LANDSCAPE

To order this report:

World Osteoporosis Therapeutics Market

More market research reports here!

Contact Information